Literature DB >> 27432980

Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing.

Franklin T Moutos1, Katherine A Glass2, Sarah A Compton1, Alison K Ross3, Charles A Gersbach4, Farshid Guilak5, Bradley T Estes6.   

Abstract

Biological resurfacing of entire articular surfaces represents an important but challenging strategy for treatment of cartilage degeneration that occurs in osteoarthritis. Not only does this approach require anatomically sized and functional engineered cartilage, but the inflammatory environment within an arthritic joint may also inhibit chondrogenesis and induce degradation of native and engineered cartilage. The goal of this study was to use adult stem cells to engineer anatomically shaped, functional cartilage constructs capable of tunable and inducible expression of antiinflammatory molecules, specifically IL-1 receptor antagonist (IL-1Ra). Large (22-mm-diameter) hemispherical scaffolds were fabricated from 3D woven poly(ε-caprolactone) (PCL) fibers into two different configurations and seeded with human adipose-derived stem cells (ASCs). Doxycycline (dox)-inducible lentiviral vectors containing eGFP or IL-1Ra transgenes were immobilized to the PCL to transduce ASCs upon seeding, and constructs were cultured in chondrogenic conditions for 28 d. Constructs showed biomimetic cartilage properties and uniform tissue growth while maintaining their anatomic shape throughout culture. IL-1Ra-expressing constructs produced nearly 1 µg/mL of IL-1Ra upon controlled induction with dox. Treatment with IL-1 significantly increased matrix metalloprotease activity in the conditioned media of eGFP-expressing constructs but not in IL-1Ra-expressing constructs. Our findings show that advanced textile manufacturing combined with scaffold-mediated gene delivery can be used to tissue engineer large anatomically shaped cartilage constructs that possess controlled delivery of anticytokine therapy. Importantly, these cartilage constructs have the potential to provide mechanical functionality immediately upon implantation, as they will need to replace a majority, if not the entire joint surface to restore function.

Entities:  

Keywords:  cartilage repair; gene therapy; mesenchymal stem cell; osteoarthritis; tissue engineering

Mesh:

Substances:

Year:  2016        PMID: 27432980      PMCID: PMC4978289          DOI: 10.1073/pnas.1601639113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

1.  Boundary mode frictional properties of engineered cartilaginous tissues.

Authors:  J P Gleghorn; A R C Jones; C R Flannery; L J Bonassar
Journal:  Eur Cell Mater       Date:  2007-08-04       Impact factor: 3.942

2.  Soluble mediators in posttraumatic wrist and primary knee osteoarthritis.

Authors:  Teun Teunis; Michiel Beekhuizen; Gerjo V M Van Osch; Arnold H Schuurman; Laura B Creemers; L Paul van Minnen
Journal:  Arch Bone Jt Surg       Date:  2014-09-15

Review 3.  Role of proinflammatory cytokines in the pathophysiology of osteoarthritis.

Authors:  Mohit Kapoor; Johanne Martel-Pelletier; Daniel Lajeunesse; Jean-Pierre Pelletier; Hassan Fahmi
Journal:  Nat Rev Rheumatol       Date:  2010-11-30       Impact factor: 20.543

Review 4.  Comparative review of growth factors for induction of three-dimensional in vitro chondrogenesis in human mesenchymal stem cells isolated from bone marrow and adipose tissue.

Authors:  Jennifer L Puetzer; John N Petitte; Elizabeth G Loboa
Journal:  Tissue Eng Part B Rev       Date:  2010-08       Impact factor: 6.389

5.  Comparative study of the intrinsic mechanical properties of the human acetabular and femoral head cartilage.

Authors:  K A Athanasiou; A Agarwal; F J Dzida
Journal:  J Orthop Res       Date:  1994-05       Impact factor: 3.494

6.  Implantation of scaffold-free engineered cartilage constructs in a rabbit model for chondral resurfacing.

Authors:  Jillian M Brenner; Nicole M Ventura; M Yat Tse; Andrew Winterborn; Davide D Bardana; Stephen C Pang; Mark B Hurtig; Stephen D Waldman
Journal:  Artif Organs       Date:  2013-10-29       Impact factor: 3.094

Review 7.  Overview of existing cartilage repair technology.

Authors:  Allison G McNickle; Matthew T Provencher; Brian J Cole
Journal:  Sports Med Arthrosc Rev       Date:  2008-12       Impact factor: 1.985

8.  Engineering graded tissue interfaces.

Authors:  Jennifer E Phillips; Kellie L Burns; Joseph M Le Doux; Robert E Guldberg; Andrés J García
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

9.  Chondrogenic differentiation of human subchondral progenitor cells is affected by synovial fluid from donors with osteoarthritis or rheumatoid arthritis.

Authors:  Jan Philipp Krüger; Michaela Endres; Katja Neumann; Bruno Stuhlmüller; Lars Morawietz; Thomas Häupl; Christian Kaps
Journal:  J Orthop Surg Res       Date:  2012-03-13       Impact factor: 2.359

10.  Interleukin-1 beta and tumor necrosis factor alpha inhibit migration activity of chondrogenic progenitor cells from non-fibrillated osteoarthritic cartilage.

Authors:  Helga Joos; Anja Wildner; Cathrin Hogrefe; Heiko Reichel; Rolf E Brenner
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more
  35 in total

1.  A Synthetic Gene Circuit for Self-Regulating Delivery of Biologic Drugs in Engineered Tissues.

Authors:  Lara Pferdehirt; Alison K Ross; Jonathan M Brunger; Farshid Guilak
Journal:  Tissue Eng Part A       Date:  2019-05       Impact factor: 3.845

2.  Specific, Sensitive, and Stable Reporting of Human Mesenchymal Stromal Cell Chondrogenesis.

Authors:  Rodolfo E De la Vega; Maximiliano Scheu; Lennart A Brown; Christopher H Evans; Elisabeth Ferreira; Ryan M Porter
Journal:  Tissue Eng Part C Methods       Date:  2019-03       Impact factor: 3.056

Review 3.  Biomaterial-Guided Gene Delivery for Musculoskeletal Tissue Repair.

Authors:  Justin L Madrigal; Roberta Stilhano; Eduardo A Silva
Journal:  Tissue Eng Part B Rev       Date:  2017-03-10       Impact factor: 6.389

Review 4.  Regenerative medicine in 2016: Important milestones on the way to clinical translation.

Authors:  Daniel A Grande
Journal:  Nat Rev Rheumatol       Date:  2017-01-05       Impact factor: 20.543

5.  Chondrogenic, hypertrophic, and osteochondral differentiation of human mesenchymal stem cells on three-dimensionally woven scaffolds.

Authors:  Benjamin L Larson; Sarah N Yu; Hyoungshin Park; Bradley T Estes; Franklin T Moutos; Cameron J Bloomquist; Patrick B Wu; Jean F Welter; Robert Langer; Farshid Guilak; Lisa E Freed
Journal:  J Tissue Eng Regen Med       Date:  2019-07-18       Impact factor: 3.963

Review 6.  Designer Stem Cells: Genome Engineering and the Next Generation of Cell-Based Therapies.

Authors:  Farshid Guilak; Lara Pferdehirt; Alison K Ross; Yun-Rak Choi; KelseyH Collins; Robert J Nims; Dakota B Katz; Molly Klimak; Suzanne Tabbaa; Christine T N Pham
Journal:  J Orthop Res       Date:  2019-05-02       Impact factor: 3.494

7.  Osteoarthritis: Joint resurfacing possibilities loom large.

Authors:  Sarah Onuora
Journal:  Nat Rev Rheumatol       Date:  2016-08-04       Impact factor: 20.543

8.  Biocompatibility and bioactivity of an FGF-loaded microsphere-based bilayer delivery system.

Authors:  Dong Hwa Kim; Julianne Huegel; Brittany L Taylor; Courtney A Nuss; Stephanie N Weiss; Louis J Soslowsky; Robert L Mauck; Andrew F Kuntz
Journal:  Acta Biomater       Date:  2020-05-16       Impact factor: 8.947

9.  CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues.

Authors:  Jonathan M Brunger; Ananya Zutshi; Vincent P Willard; Charles A Gersbach; Farshid Guilak
Journal:  Arthritis Rheumatol       Date:  2017-03-31       Impact factor: 10.995

10.  Genetic Engineering of Mesenchymal Stem Cells for Differential Matrix Deposition on 3D Woven Scaffolds.

Authors:  Nguyen P T Huynh; Jonathan M Brunger; Catherine C Gloss; Franklin T Moutos; Charles A Gersbach; Farshid Guilak
Journal:  Tissue Eng Part A       Date:  2018-07-13       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.